Should ticagrelor (Brilinta) be prescribed for coronary artery disease?

Should Ticagrelor (Brilinta) Be Given for CAD?

Yes, ticagrelor should be given for coronary artery disease, but the specific indication, duration, and patient selection depend critically on the clinical presentation—acute coronary syndrome (ACS) versus stable/chronic CAD—and the balance between ischemic and bleeding risk.

Clinical Context Determines Use

For Acute Coronary Syndrome (ACS)

Ticagrelor is strongly recommended and superior to clopidogrel in ACS patients 1, 2, 1, 3. The evidence here is robust:

• Class I recommendation (ACC/AHA): In ACS patients treated with PCI, ticagrelor 180 mg loading dose followed by 90 mg twice daily for at least 12 months is reasonable to use in preference to clopidogrel 1
• Class IIa recommendation (ESC): Ticagrelor is recommended over clopidogrel unless bleeding risk outweighs ischemic benefit 2
• FDA-approved indication: Ticagrelor reduces cardiovascular death, MI, and stroke in ACS patients, with superiority over clopidogrel demonstrated in the first 12 months 3

The PLATO trial established that ticagrelor 90 mg twice daily reduced ischemic complications and stent thrombosis compared to clopidogrel, with more non-CABG bleeding but no difference in CABG-related bleeding 4, 5.

After the first year post-ACS: Reduce to ticagrelor 60 mg twice daily if continuing beyond 12 months 1, 4, 3. The PEGASUS-TIMI 54 trial showed that in patients 1-3 years post-MI with high-risk features (age >65, diabetes, multivessel CAD, CKD), ticagrelor 60 mg twice daily reduced ischemic events but increased TIMI major bleeding 6, 7.

For Stable/Chronic Coronary Syndrome (CCS)

The recommendation is more nuanced and generally weaker for stable CAD without prior MI:

• Class IIb recommendation (ESC 2024): Ticagrelor 90 mg twice daily monotherapy may be considered in selected high ischemic risk patients without high bleeding risk, but evidence is weaker than for aspirin or clopidogrel 6
• FDA indication exists: For CAD patients at high risk of first MI or stroke, particularly those with type 2 diabetes, ticagrelor 60 mg twice daily is indicated 3
• Critical caveat: The THEMIS trial showed that in diabetic patients with stable CAD but no prior MI/stroke, ticagrelor plus aspirin reduced ischemic events but increased major bleeding. Benefit was only seen in the subgroup with prior PCI 8, 9

For stable CAD post-PCI: Clopidogrel remains the standard P2Y12 inhibitor 2, 6. The ALPHEUS trial showed ticagrelor did not reduce PCI-related MI in CCS patients but increased minor bleeding compared to clopidogrel 6.

Practical Algorithm for Decision-Making

Step 1: Identify Clinical Presentation

• ACS (STEMI, NSTE-ACS) or recent MI (<12 months) → Proceed to Step 2
• Stable CAD, no recent ACS → Proceed to Step 3

Step 2: ACS Patients

• Loading dose: Ticagrelor 180 mg at presentation 1, 3
• Maintenance: 90 mg twice daily for 12 months 1
• Aspirin: 75-100 mg daily (81 mg preferred) 1
• After 12 months:
  • If high ischemic risk (diabetes, multivessel CAD, PAD, CKD) and low bleeding risk → Continue ticagrelor 60 mg twice daily 6, 7
  • Otherwise → Consider de-escalation to clopidogrel or aspirin monotherapy

Step 3: Stable CAD Patients

• Default: Aspirin or clopidogrel monotherapy 6
• Consider ticagrelor 60 mg twice daily if:
  • Type 2 diabetes AND high ischemic risk features (age >65, multivessel CAD, PAD, CKD) 6, 3
  • Prior PCI within past 1-3 years 8, 9
  • AND low bleeding risk (no prior bleeding, no anticoagulation, PRECISE-DAPT <25) 2

Key Contraindications and Cautions

Absolute contraindications 3:

• History of intracranial hemorrhage
• Active pathological bleeding
• Hypersensitivity to ticagrelor

Relative contraindications/cautions:

• High bleeding risk (PRECISE-DAPT ≥25) 2
• Concurrent oral anticoagulation (use clopidogrel instead) 10, 11
• Severe hepatic impairment 3
• Urgent CABG planned (discontinue 5 days prior) 1

Common Pitfalls to Avoid

1. Don't use ticagrelor with high-dose aspirin: Aspirin should be 75-100 mg daily, not >100 mg, to minimize bleeding 1, 4, 1

2. Don't assume all CAD patients benefit equally: The benefit in stable CAD is confined to high-risk subgroups, particularly those with diabetes and prior PCI 8, 9

3. Don't ignore dyspnea: Ticagrelor causes dyspnea in ~14% of patients, usually self-limited and benign, but can affect adherence 5, 3

4. Don't combine with other P2Y12 inhibitors: Never use ticagrelor with clopidogrel or prasugrel simultaneously 3

5. Don't forget drug interactions: Avoid strong CYP3A4 inhibitors/inducers; monitor digoxin levels; be cautious with high-dose statins (>40 mg simvastatin/lovastatin) 3

Bleeding vs. Ischemic Risk Balance

The decision ultimately hinges on individual risk stratification:

• High ischemic risk features: Recent ACS, diabetes, multivessel CAD, PAD, CKD, prior stent thrombosis, complex PCI 6, 7
• High bleeding risk features: Age >75, low body weight (<60 kg), prior bleeding, anemia, chronic kidney disease, concurrent anticoagulation, PRECISE-DAPT ≥25 2, 12

In patients with both high ischemic AND high bleeding risk, shorter DAPT duration (3-6 months) followed by single antiplatelet therapy may be reasonable, though ticagrelor monotherapy after brief DAPT shows promise in reducing bleeding without increasing ischemic events 13.